AK MEDICAL HOLDINGS LIMITED Financials AK Medical Holdings Limited
Equities
1789
KYG020141019
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.77 HKD | +4.15% |
|
+19.96% | -7.83% |
| Apr. 22 | AK Medical Holdings' Surgical Robot Gets NMPA's Nod | MT |
| Apr. 18 | Eric Wang to Retire as an Independent Non-Executive Director of AK Medical Holdings Limited | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,965 | 8,260 | 12,637 | 6,000 | 9,647 | 5,992 | 5,992 | - |
| Enterprise Value (EV) 1 | 3,545 | 7,744 | 11,951 | 5,172 | 9,026 | 6,383 | 5,790 | 5,793 |
| P/E ratio | 27.2 x | 31.4 x | 40.5 x | 67.2 x | 48 x | 35.6 x | 22.7 x | 17.7 x |
| Yield | 0.79% | 0.87% | 0.3% | 0.38% | 0.61% | 1.12% | 1.19% | 1.56% |
| Capitalization / Revenue | 6.6 x | 8.91 x | 12.2 x | 7.88 x | 9.17 x | 5.84 x | 4.25 x | 3.38 x |
| EV / Revenue | 5.9 x | 8.36 x | 11.5 x | 6.79 x | 8.58 x | 5.84 x | 4.11 x | 3.26 x |
| EV / EBITDA | 18.5 x | 23.1 x | 27.8 x | 29.8 x | 31.2 x | 23.1 x | 14.5 x | 11.7 x |
| EV / FCF | 65.1 x | - | 99.6 x | 43.9 x | 74.5 x | 50.7 x | 51.9 x | 45.3 x |
| FCF Yield | 1.54% | - | 1% | 2.28% | 1.34% | 1.97% | 1.93% | 2.21% |
| Price to Book | 4.7 x | 7.32 x | 6.11 x | 2.95 x | 4.3 x | 2.42 x | 2.28 x | 2.05 x |
| Nbr of stocks (in thousands) | 1,040,475 | 1,052,700 | 1,115,500 | 1,115,700 | 1,115,750 | 1,121,921 | 1,121,921 | - |
| Reference price 2 | 3.811 | 7.846 | 11.33 | 5.378 | 8.646 | 5.341 | 5.341 | 5.341 |
| Announcement Date | 3/25/19 | 3/23/20 | 3/22/21 | 3/24/22 | 3/27/23 | 3/26/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 600.6 | 926.7 | 1,035 | 761.4 | 1,052 | 1,094 | 1,410 | 1,775 |
| EBITDA 1 | 192 | 334.8 | 429.4 | 173.6 | 289.2 | 276.1 | 399.2 | 495.4 |
| EBIT 1 | 171.2 | 302.7 | 368.9 | 93.46 | 208.8 | 185.1 | 301.5 | 388 |
| Operating Margin | 28.51% | 32.66% | 35.63% | 12.27% | 19.85% | 16.92% | 21.39% | 21.85% |
| Earnings before Tax (EBT) 1 | 174.5 | 321.4 | 376.6 | 108.6 | 240.3 | 231.1 | 324.5 | 413 |
| Net income 1 | 144.9 | 267 | 314 | 92.62 | 204.8 | 182.1 | 264.4 | 338 |
| Net margin | 24.13% | 28.81% | 30.33% | 12.16% | 19.46% | 16.65% | 18.75% | 19.04% |
| EPS 2 | 0.1400 | 0.2500 | 0.2800 | 0.0800 | 0.1800 | 0.1600 | 0.2357 | 0.3010 |
| Free Cash Flow 1 | 54.46 | - | 120 | 117.9 | 121.2 | 97 | 111.5 | 128 |
| FCF margin | 9.07% | - | 11.59% | 15.48% | 11.52% | 7.52% | 7.91% | 7.21% |
| FCF Conversion (EBITDA) | 28.37% | - | 27.95% | 67.9% | 41.91% | 29.67% | 27.93% | 25.84% |
| FCF Conversion (Net income) | 37.58% | - | 38.22% | 127.26% | 59.19% | 38.73% | 42.17% | 37.87% |
| Dividend per Share 2 | 0.0300 | 0.0686 | 0.0335 | 0.0204 | 0.0526 | 0.0600 | 0.0633 | 0.0833 |
| Announcement Date | 3/25/19 | 3/23/20 | 3/22/21 | 3/24/22 | 3/27/23 | 3/26/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 437.8 | 488.9 | 479 | 556.4 | 447.6 | 313.8 | 531.2 | 520.8 | 648.7 | 445.2 | 649.1 | 760.7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | 126.8 | -33.38 | 129.9 | 78.9 | 142.7 | 42.45 | 137.2 | 153.8 |
| Operating Margin | - | - | - | - | 28.34% | -10.64% | 24.45% | 15.15% | 21.99% | 9.54% | 21.14% | 20.21% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | 126 | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | 23.73% | - | - | - | - | - |
| EPS 2 | - | - | - | - | 0.1000 | - | 0.1100 | 0.0700 | 0.1200 | 0.0400 | 0.1200 | 0.1100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/26/19 | 3/23/20 | 8/24/20 | 3/22/21 | 8/24/21 | 3/24/22 | 8/30/22 | 3/27/23 | 8/22/23 | 3/26/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 420 | 516 | 686 | 828 | 621 | 1,075 | 203 | 200 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 54.5 | - | 120 | 118 | 121 | 97 | 112 | 128 |
| ROE (net income / shareholders' equity) | 19.2% | 27.3% | 19.9% | 4.55% | 9.58% | 10.5% | 10.8% | 12.7% |
| ROA (Net income/ Total Assets) | 14.9% | 20.7% | 15.7% | 3.56% | 7.61% | 9.08% | 8.69% | 10% |
| Assets 1 | 975.2 | 1,288 | 2,005 | 2,605 | 2,690 | 2,760 | 3,044 | 3,371 |
| Book Value Per Share 2 | 0.8100 | 1.070 | 1.850 | 1.830 | 2.010 | 2.210 | 2.340 | 2.600 |
| Cash Flow per Share 2 | - | 0.2800 | 0.3400 | - | 0.2200 | 0.2000 | 0.3000 | 0.2900 |
| Capex 1 | 73.5 | 107 | 100 | 58.8 | 122 | 135 | 177 | 203 |
| Capex / Sales | 12.24% | 11.54% | 9.69% | 7.72% | 11.57% | 10.42% | 12.52% | 11.43% |
| Announcement Date | 3/25/19 | 3/23/20 | 3/22/21 | 3/24/22 | 3/27/23 | 3/26/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.341
CNY
Average target price
7.438
CNY
Spread / Average Target
+39.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.83% | 827M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- 1789 Stock
- Financials AK Medical Holdings Limited
